Meeting
2023 ASCO Genitourinary Cancers Symposium
Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC.
Authors
Elshad Hasanov
University of Texas MD Anderson Cancer Center, Houston, TX
Elshad Hasanov , Lesley Flynt , Rebecca Slack Tidwell , Hyunsoo Hwang , Roserika Brooks , Lauren Michelle King , Travis Solley , Dahlia Mack , Yuko Yamamura , Colin Hayward , Aradhana M. Venkatesan , Eric Jonasch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS749)
DOI
10.1200/JCO.2023.41.6_suppl.TPS749
Abstract #
TPS749
Poster Bd #
N7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC.
First Author: Elshad Hasanov
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.
First Author: Elshad Hasanov
Poster
2022 ASCO Genitourinary Cancers Symposium
Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.
First Author: Thomas Powles
Poster
2021 ASCO Annual Meeting
Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.
First Author: Andrea B. Apolo